Fabry's disease classification: Difference between revisions
Jump to navigation
Jump to search
Ghsanadgol (talk | contribs) |
Ghsanadgol (talk | contribs) |
||
| Line 11: | Line 11: | ||
! | ! | ||
!Age of onset | !Age of onset | ||
!Severity | !Severity | ||
![[alpha-Gal A]] activity | ![[alpha-Gal A]] activity | ||
!Average age of death | |||
|- | |- | ||
|Classic | |Classic | ||
| Line 18: | Line 19: | ||
|severe | |severe | ||
|no activity or<1% of the normal mean | |no activity or<1% of the normal mean | ||
|41 years | |||
|- | |- | ||
|Atypical (later onset) | |Atypical (later onset) | ||
| Line 23: | Line 25: | ||
|less severe | |less severe | ||
|2 to 30% of the normal mean | |2 to 30% of the normal mean | ||
|>60 years<ref name="pmid17347915">{{cite journal| author=Eng CM, Fletcher J, Wilcox WR, Waldek S, Scott CR, Sillence DO | display-authors=etal| title=Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. | journal=J Inherit Metab Dis | year= 2007 | volume= 30 | issue= 2 | pages= 184-92 | pmid=17347915 | doi=10.1007/s10545-007-0521-2 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17347915 }}</ref> | |||
|} | |} | ||
<nowiki>*</nowiki>[[Heterozygous]] females can categorized in both groups based on the severity of the disease, from severe classic ones to less severe atypical and even no symptoms.<ref name="pmid18037317">{{cite journal| author=Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U | display-authors=etal| title=Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. | journal=Mol Genet Metab | year= 2008 | volume= 93 | issue= 2 | pages= 112-28 | pmid=18037317 | doi=10.1016/j.ymgme.2007.09.013 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18037317 }} </ref> | <nowiki>*</nowiki>[[Heterozygous]] females can categorized in both groups based on the severity of the disease, from severe classic ones to less severe atypical and even no symptoms.<ref name="pmid18037317">{{cite journal| author=Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U | display-authors=etal| title=Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. | journal=Mol Genet Metab | year= 2008 | volume= 93 | issue= 2 | pages= 112-28 | pmid=18037317 | doi=10.1016/j.ymgme.2007.09.013 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18037317 }} </ref> | ||
===Based upon complications=== | ===Based upon complications=== | ||
*Cardiac variant | *Cardiac variant | ||
*Renal variant | *Renal variant | ||
Revision as of 20:22, 12 March 2022
|
Fabry's disease Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Fabry's disease classification On the Web |
|
American Roentgen Ray Society Images of Fabry's disease classification |
|
Risk calculators and risk factors for Fabry's disease classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Classification
===Based upon Phenotypes===[1] [2]
| Age of onset | Severity | alpha-Gal A activity | Average age of death | |
|---|---|---|---|---|
| Classic | Childhood (mostly) | severe | no activity or<1% of the normal mean | 41 years |
| Atypical (later onset) | Third to seventh decades | less severe | 2 to 30% of the normal mean | >60 years[3] |
*Heterozygous females can categorized in both groups based on the severity of the disease, from severe classic ones to less severe atypical and even no symptoms.[4]
Based upon complications
- Cardiac variant
- Renal variant
- Non-neuropathic form
- Neuropathic form
- Infantile form
- Juvenile form
References
- ↑ Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M; et al. (2003). "Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy". Ann Intern Med. 138 (4): 338–46. doi:10.7326/0003-4819-138-4-200302180-00014. PMID 12585833.
- ↑ Lavalle L, Thomas AS, Beaton B, Ebrahim H, Reed M, Ramaswami U; et al. (2018). "Phenotype and biochemical heterogeneity in late onset Fabry disease defined by N215S mutation". PLoS One. 13 (4): e0193550. doi:10.1371/journal.pone.0193550. PMC 5886405. PMID 29621274.
- ↑ Eng CM, Fletcher J, Wilcox WR, Waldek S, Scott CR, Sillence DO; et al. (2007). "Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry". J Inherit Metab Dis. 30 (2): 184–92. doi:10.1007/s10545-007-0521-2. PMID 17347915.
- ↑ Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U; et al. (2008). "Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry". Mol Genet Metab. 93 (2): 112–28. doi:10.1016/j.ymgme.2007.09.013. PMID 18037317.